Effect of heart failure on the outcome of COVID-19 - A meta analysis and systematic review

Emir Yonas1, Idrus Alwi2, Raymond Pranata3

  • 1Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia.

Insights

Patients with heart failure (HF) face a significantly higher risk of severe outcomes, including hospitalization, poor prognosis, and death from COVID-19. This systematic review confirms HF as a critical comorbidity impacting COVID-19 mortality.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • Comorbidities like hypertension and diabetes increase COVID-19 severity and mortality risk.
  • Heart failure (HF) is a significant comorbidity requiring investigation for its impact on COVID-19 outcomes.

Purpose of the Study:

  • To systematically review and meta-analyze the association between pre-existing heart failure (HF) and adverse outcomes in COVID-19 patients.
  • To quantify the risk of mortality and poor prognosis in COVID-19 patients with heart failure.

Main Methods:

  • Systematic literature search of major databases (PubMed, SCOPUS, etc.) using keywords 'Heart failure' and 'COVID-19'.
  • Inclusion of 18 studies with 21,640 patients for qualitative synthesis and meta-analysis.
  • Analysis of outcomes including hospitalization, severe COVID-19, ICU admission, ventilator use, and mortality.

Main Results:

  • Heart failure (HF) was significantly associated with increased hospitalization (HR 2.37) and poor outcomes (OR 2.86) in COVID-19 patients.
  • Patients with pre-existing HF exhibited a substantially higher mortality risk (OR 3.46) compared to those without HF.
  • High heterogeneity was noted across the analyzed studies for all outcomes.

Conclusions:

  • Heart failure is a critical risk factor for adverse outcomes in COVID-19, including increased hospitalization, poor prognosis, and higher mortality.
  • A significant disparity in mortality rates was observed, with COVID-19 patients who have heart failure experiencing considerably worse survival.
  • The findings underscore the importance of managing heart failure in patients diagnosed with COVID-19.
Abstract

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
527
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.4K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
483
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
119
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
606
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
717